Aimei Health extends SPAC deadline with $34K note

Aimei Health Technology Co., Ltd has extended the deadline to complete its initial business combination by one month, moving the termination date from February 6, 2026 to March 6, 2026.

Rhea-AI Filing Summary

Aimei Health Technology Co., Ltd has extended the deadline to complete its initial business combination by one month, moving the termination date from February 6, 2026 to March 6, 2026. To fund this fifteenth monthly extension, an aggregate $34,330.96 was deposited into the company’s trust account for public shareholders.

In connection with this extension, the company issued an unsecured promissory note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., each contributing $17,165.48. The note bears no interest and becomes payable when the company consummates its proposed business combination with United Hydrogen. The payees may instead convert the note into private units of Aimei Health at $10.00 per unit immediately before closing, with each unit consisting of one ordinary share and a right to receive one-fifth of one ordinary share.

Insights

SPAC and capital structure analyst

Aimei extends its SPAC deal deadline by one month using a small, convertible insider loan.

Aimei Health Technology is using a standard SPAC mechanism to gain another month, shifting the business combination deadline with United Hydrogen Group Inc. to March 6, 2026. The extension is funded by a relatively small $34,330.96 deposit into the trust account for public shareholders.

The company issued an unsecured promissory note for the same $34,330.96 to its sponsor and United Hydrogen, split equally at $17,165.48 each. The note carries no interest and is due only upon completion of the business combination, aligning repayment with a successful closing rather than the current extension date.

The payees may convert the note into private units at $10.00 per unit, each unit including one ordinary share and a right to one-fifth of a share, immediately before the transaction closes. This introduces potential equity issuance tied specifically to deal completion; actual dilution, if any, depends on whether the payees elect conversion.

8-K Event Classification

Item 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

1 item

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

FAQ

What did Aimei Health Technology Co., Ltd (AFJK) announce in this 8-K?

Aimei Health Technology extended its deadline to complete an initial business combination to March 6, 2026 and funded this one-month extension with a $34,330.96 deposit into its trust account, supported by a matching unsecured promissory note to insiders.

How much did Aimei Health (AFJK) deposit to extend its SPAC deadline?

Aimei Health deposited $34,330.96 into its trust account for public shareholders. This amount reflects the lesser of $80,000 total or $0.033 per outstanding public share for this monthly extension, funding a one-month extension of its business combination deadline.

What are the key terms of Aimei Health’s new promissory note?

The company issued an unsecured promissory note for $34,330.96 to its sponsor and United Hydrogen Group Inc., each providing $17,165.48. The note bears no interest, becomes due upon completion of the business combination with United Hydrogen, and may be converted into private units at $10.00 per unit.

Who are the payees on Aimei Health’s promissory note for AFJK?

The promissory note was issued to Aimei Health Ltd, the sponsor, and United Hydrogen Group Inc., with the total principal of $34,330.96 split evenly. Each payee contributed $17,165.48 to fund the trust account extension payment for Aimei Health’s SPAC structure.

Can the Aimei Health AFJK promissory note be converted into equity?

Yes. The payees may convert the $34,330.96 promissory note, in whole or in part, into private units at $10.00 per unit immediately before closing the business combination. Each unit consists of one ordinary share and a right to receive one-fifth of one ordinary share.

How many extensions has Aimei Health (AFJK) used under its charter?

This filing states that the one-month extension to March 6, 2026 is the fifteenth extension permitted under Aimei Health’s Amended and Restated Articles of Association, indicating multiple prior deadline extensions for completing its initial business combination.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:05 PM Learn about SEC filing dates

false 0001979005 0001979005 2026-02-12 2026-02-12 0001979005 AFJK:OrdinarySharesParValue0.0001PerShareMember 2026-02-12 2026-02-12 0001979005 AFJK:RightsExchangeableIntoOnefifthOfOneOrdinaryShareMember 2026-02-12 2026-02-12 0001979005 AFJK:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember 2026-02-12 2026-02-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

February 12, 2026

Date of Report (Date of earliest event reported)

AIMEI HEALTH TECHNOLOGY CO., LTD

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands		001-41880		N/A 00-0000000
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

10 East 53rd Street, Suite 3001 New York, NY		10022
(Address of Principal Executive Offices)		(Zip Code)

86-13758131392

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per share		AFJK		The Nasdaq Stock Market LLC
Rights, exchangeable into one-fifth of one Ordinary Share		AFJKR		The Nasdaq Stock Market LLC
Units, each consisting of one Ordinary Share and one Right		AFJKU		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

Extension of the Termination Date

An aggregate of $34,330.96 (the “Extension Payment”) has been deposited into the trust account of Aimei Health Technology Co., Ltd (the “Company”) for its public shareholders, representing the lessor of (i) $80,000 for all outstanding public shares and (ii) $0.033 for each outstanding public share for each monthly extension, which enables the Company to further extend the period of time it has to consummate its initial business combination by one month (the “Extension”) from February 6, 2026 to March 6, 2026 (the “Termination Date”). The Extension is the fifteenth extension permitted under the Amended and Restated Articles of Association of the Company currently in effect.

Promissory Note

In connection with the Extension, the Company issued, on February 12, 2026, an unsecured promissory note in the total principal amount of $34,330.96 (the “Promissory Note”) to Aimei Health Ltd, a Cayman Islands exempted company (the “Sponsor”) and United Hydrogen Group Inc., an exempted company with limited liability incorporated in the Cayman Islands (“United Hydrogen,” and together with the Sponsor, the “Payees”). The amount was equally divided between the Payees, with each contributing $17,165.48, to fund the Extension Payment. The Promissory Note does not bear interest and the principal thereunder becomes due and payable upon the date on which the Company consummates a business combination with United Hydrogen (the “Business Combination”). The Payees have the right, but not the obligation, to convert the Promissory Note, in whole or in part, into private units of the Company, at a price of $10.00 per unit, each consisting of one ordinary share and one right to receive one-fifth (1/5) of one ordinary share of the Company, immediately prior to the consummation of the Business Combination, by providing the Company with written notices of their intention to convert the Promissory Note at least two business days prior to the closing of the Business Combination.

The foregoing description of the Promissory Note is not complete and is qualified in its entirety by reference to the text of such document, which is filed as Exhibit 10.1 hereto and which is incorporated herein by reference.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		Promissory Note, dated February 12, 2026, by and among Aimei Health Technology Co., Ltd, Aimei Health Ltd, and United Hydrogen Group Inc.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 13, 2026

	Aimei Health Technology Co., Ltd
	By:	/s/ Junheng Xie
	Name:	Junheng Xie
	Title:	Chief Executive Officer and Director
		(Principal Executive Officer)

Filing Exhibits & Attachments

5 documents

Agreements & Contracts

• EX-10.1 EX-10.1 44.0 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 4.0 KB
• EX-101 XBRL DEFINITION FILE 26.5 KB
• EX-101 XBRL LABEL FILE 36.6 KB
• EX-101 XBRL PRESENTATION FILE 25.2 KB